Dihexa is barely a peptide, and its literature makes claims that the size of the molecule makes remarkable. It is a heavily modified derivative of a four-residue fragment of angiotensin IV, engineered until it is small, lipophilic and stable enough to behave more like a drug-like small molecule than like anything else in this catalogue. The proposed mechanism runs through a growth-factor receptor with a serious pedigree. Reading the compound means holding the potency claims and the mechanism's implications in view at the same time.
What it is
The starting point is angiotensin IV, itself a fragment of the better-known angiotensin II. Its N-terminal residues were found to have effects on memory-related tasks in rodents in work spanning decades, but the fragment is cleared within seconds and does not cross membranes. Dihexa is the product of a sustained effort to fix both problems by modification rather than by the usual half-life strategies.
| Feature | Angiotensin IV | Dihexa |
|---|---|---|
| Core residues | Val-Tyr-Ile-His-Pro-Phe | Tyr-Ile, from the N-terminal region |
| N-terminus | Free | Capped with a hexanoyl group |
| C-terminus | Free carboxyl | 6-aminohexanoic amide |
| Character | Charged, hydrophilic | Lipophilic, membrane-permeant |
| Stability | Seconds | Hours to days |
| Approx. mass | 774 Da | 504 Da |
The result is a molecule of about 500 daltons with two natural residues at its centre and non-peptide groups at both ends — the name records the hexanoyl cap and the aminohexanoic tail. It is closer in properties to a conventional small molecule than to a peptide, which is why the handling rules that apply to the rest of the catalogue largely do not apply here.
What is the proposed mechanism?
Potentiation of hepatocyte growth factor at its receptor, c-Met. The proposal is that Dihexa binds HGF and increases its ability to activate the receptor, rather than binding c-Met directly — an allosteric effect on the ligand rather than agonism at the receptor. HGF–c-Met signalling drives cell growth, motility and survival, and in the nervous system is associated with synapse formation, which is the link to the memory-related findings. It is a named, testable target, which puts Dihexa in a different category from short neuropeptides with no established receptor.
Why is c-Met a reason for caution rather than only interest?
Because it is a proto-oncogene. HGF–c-Met signalling is one of the pathways most consistently found activated in tumours, and inhibitors of it are an established class in oncology. A compound that potentiates the pathway is therefore, by its own proposed mechanism, doing something the field otherwise works to suppress. That is not a claim about what Dihexa does in any system; it is an observation that the mechanism, if correct, carries an implication the enthusiasm around the compound tends to leave unstated. Any serious research programme with it would want to characterise proliferation effects alongside the intended ones.
Reading the potency claims
The original reports describe activity at picomolar concentrations — several orders of magnitude below where most peptides act. Three things are worth holding against that number.
It comes from few sources. The primary literature is concentrated in the laboratory that developed the compound, and independent replication of the potency figures is thin. That is the same reading discipline as for BPC-157 or Epithalon, applied to a molecule with a more conventional mechanism.
Picomolar potency requires picomolar handling. At those concentrations, loss to plasticware can exceed what is in solution, and a lipophilic molecule binds plastic more readily than a charged one. A working dilution at 10 pM in an ordinary tube may contain very little Dihexa by the time it reaches a well.
An allosteric potentiator needs its ligand present. If the mechanism is potentiation of HGF, the compound does nothing in a system with no HGF. A null result without HGF in the medium is uninformative, and a positive result without HGF would contradict the proposed mechanism and deserve more scrutiny, not less.
How is Dihexa handled differently from a peptide?
It is lipophilic, so it does not dissolve readily in water. The usual route is a small volume of DMSO or ethanol first, then dilution into aqueous medium — and the organic solvent then becomes part of the vehicle and belongs in the control well. It is stable in solution far longer than an ordinary short peptide, because both termini are capped and the two natural residues carry no fast degradation sites. And it crosses membranes, so cell entry is not the barrier it is for a charged tetrapeptide. In each respect it behaves as a small molecule, and the rules for reconstituted peptides mostly do not apply.
Does a certificate for Dihexa look like a peptide certificate?
Mostly, with one difference in emphasis. Identity by mass and purity by HPLC apply as usual, and the compound is characterised that way. Net peptide content is close to meaningless for a 500-dalton molecule with non-peptide groups at both ends; what matters instead is residual solvent, since the synthesis and purification involve organic solvents that a lipophilic product retains more readily than a lyophilised peptide does. Reading each panel for what it answers means, here, weighting the solvent panel higher and the content panel lower than usual.
What would make a Dihexa result convincing?
An HGF-dependent effect that disappears when HGF is withheld, is blocked by a c-Met inhibitor, and is reproduced by a group without a stake in the compound — with the concentration in the well confirmed rather than calculated, given how little material is present at picomolar levels. The mechanism is specific enough to be tested cleanly. That is an advantage over most of the catalogue, and it is worth using.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
